BackIntelligent Medicine Acquisition - Units (1 Ord Share Class A & 1/2 War) Overview

Intelligent Medicine Acquisition - Units (1 Ord Share Class A & 1/2 War) Common Stock

Latest common stock for IQMDU: $210M.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$213.26M
1.00% YoYΔ $2.11M vs prior year quarter

Peer trimmed avg / median

Loading

Intelligent Medicine Acquisition - Units (1 Ord Share Class A & 1/2 War) Common Stock History

Loading

Intelligent Medicine Acquisition - Units (1 Ord Share Class A & 1/2 War) vs. peers: Common Stock Comparison

Loading

Intelligent Medicine Acquisition - Units (1 Ord Share Class A & 1/2 War) Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Intelligent Medicine Acquisition - Units (1 Ord Share Class A & 1/2 War) (IQMDU) FAQ

The latest common stock for IQMDU is $210M as of December 2022. That compares with $210M in the prior-year period — up 1.0% year over year. Investors often review this figure alongside Intelligent Medicine Acquisition - Units (1 Ord Share Class A & 1/2 War)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, IQMDU's common stock moved from $210M to $210M — a 1.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Intelligent Medicine Acquisition - Units (1 Ord Share Class A & 1/2 War)'s operating scale or balance-sheet position.

A common stock figure of $210M for IQMDU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting IQMDU's common stock ($210M), review year-over-year change from $210M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.